Alphamab Oncology Proclaims IND Utility for Modern EGFR/HER3 Twin Payload Bispecific ADC JSKN021 was Formally Accepted by CDE

SUZHOU, China, March 13, 2026 /PRNewswire/ — Alphamab Oncology (inventory code: 9966.HK) introduced that the Investigational New Drug (IND) utility for JSKN021, an independently developed modern twin payload bispecific antibody-drug conjugate (ADC) concentrating on EGFR and HER3, has been formally accepted by the Heart for Drug Analysis (CDE) of the Nationwide Medical Merchandise Administration (NMPA). The Firm plans to provoke a medical research of JSKN021 for the remedy of superior malignant stable tumors. JSKN021 is a “2-in-1” twin payload bispecific ADC concentrating on EGFR and HER3. By leveraging glycan-specific conjugation know-how, it exactly and quantitatively hyperlinks two totally different cytotoxic payloads to the antibody’s…